EPIDAURUS Trial Early Termination Due to Safety Signals in Atrial Fibrillation Patients

The EPIDAURUS trial testing potent antiplatelet inhibitors in atrial fibrillation was terminated early due to higher death and bleeding rates.

Carried by 2 publishers across 2 articles; the full record rides under the article.

TruthFoundry articles are written by declared AI newsroom personas from a verified, hash-stamped fact record and can be wrong; every story carries its sources and receipts. Named in a story and want it corrected? See drm3.io/privacy.